Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Mydecine Innovations Group Inc
(OP:
MYCOF
)
0.0044
-0.0063 (-58.88%)
Streaming Delayed Price
Updated: 1:04 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mydecine Innovations Group Inc
< Previous
1
2
3
Next >
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Mind Medicine to Study Effect of Time on LSD Microdosing
December 17, 2021
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a...
Via
Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
December 01, 2021
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
November 16, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) (FSE: 0NF...
Via
Benzinga
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
November 14, 2021
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.
Via
Talk Markets
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
November 04, 2021
Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100. Beck&rsq...
Via
Benzinga
Topics
Death
Exposures
Death
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
October 24, 2021
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.
Via
Talk Markets
Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
October 20, 2021
The National Institutes of Health awarded a nearly $4 million grant meant to fund research on psilocybin, the act...
Via
Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
October 15, 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.
Via
Talk Markets
September Summary: Cannabis-Based Vs. Psychedelic Compounds-Based Drug Stock Performances
October 01, 2021
Which index out-performed in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?
Via
Talk Markets
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
September 27, 2021
Psychedelics and mycology company Mydecine Innovations Group Inc. (NEO: MYCO) (OTC:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Which Psychedelic Stock ETF Is Right For You?
September 18, 2021
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.
Via
Talk Markets
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
September 13, 2021
Last Week In Psychedelics:
Via
Benzinga
Cannabis And Psychedelic Drug Stock Performances Were Mixed Last Week
September 11, 2021
The performance of the psychedelic-focused index components substantially outshone the weed stocks.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Psychedelic Drug Industry Report Card For 2021
September 01, 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development.
Via
Talk Markets
Magic Mushroom Drug Stock Performances YTD
August 29, 2021
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”.
Via
Talk Markets
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
August 26, 2021
On Wednesday, PharmaDrug Inc. (CSE:PHRX) (OTC:
Via
Benzinga
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
August 23, 2021
Beckley Psytech Closes $80 Million Series B Beckley Psytech announced
Via
Benzinga
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
August 18, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) has signe...
Via
Benzinga
Which Psychedelic Drug Stock Category Outperformed Last Week
August 10, 2021
Which has performed best YTD, the Pure-Play Marijuana Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Which Psychedelic Drug Has The Most Commercial Potential?
August 10, 2021
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.
Via
Talk Markets
Marijuana Vs. Mushroom Psychedelic Drug Stocks: A Current & YTD Performance Comparison
July 24, 2021
We identify the performance of the top 8 clinical-stage psychedelic companies in each of the marijuana and mushroom drug stock categories during the past 5 trading days, July to date, and YTD.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
How The Pot And Psychedelic Stocks Performed Last Week And YTD
July 13, 2021
Approximately 100 clinical-stage marijuana and mushroom/ketamine psychedelic drug stocks now trade on the various North American stock exchanges.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
How To Invest In "Magic Mushrooms" (Psychedelics)
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
July 07, 2021
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps...
Via
Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
July 07, 2021
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D...
Via
Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
July 02, 2021
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.